Ghassan K. Abou-Alfa, MD:The workup that was done for the patient is very appropriate. Actually, I’m very happy to see that the patient, other than the MRI [magnetic resonance imaging], did have a biopsy. Biopsies are very critical. We definitely should not treat patients with extensive disease without knowing really what they have. Biopsies nowadays are critical for HCC because, number one, you want to make sure that we’re really treating HCC, not necessarily that things might look, based on LI-RADS [Liver Imaging Reporting and Data Systems] as HCC, but sometimes they might differ. Add to this, in about 10[%] to 20% of the cases combined HCC plus cholangiocarcinoma can occur. And add to this also some genetic evaluation of the tumor can be helpful. It’s not necessarily up to gear in HCC compared [with] other diseases, but nonetheless, some choices of therapy might be really driven by the general evaluation of the genetic makeup of the tumor.
With this, again, imaging could be a CAT Scan, chest, abdomen, and pelvis. A CT [computed tomography] of the chest, MRI…[of]the pelvis if patient’s allergic to contrast, or despite intervention, or if it’s a preference. These are all good. And, of course a biopsy is appropriate, per se.
No doubt that the patient did very well on the embolizations that happened three times. And truly in general we don’t have a limitation how many embolizations or how frequent should they happen. Maybe I would say short of Japan that really have defined a little bit of guidance in regard to how many and how frequent. Nonetheless, I think reasoning is very important to make sure that the patient, if they are benefiting, by all means do it, but if the recurrence of the disease happened rather more frequent in between the embolization or they required so many embolization, time to really talk to other experts in the field. And this is really what brings in the multidisciplinary approach to therapy and to the management of patients with HCC. This required the involvement and the contribution of the hepatologist, the medical oncologist, and of course the interventional radiologist, and of course if there was a resectable disease the surgeon, transplant surgeon, if needed, and many others as well.
Transcript edited for clarity.
A 60-Year-Old Male With Unresectable HCC and a History of HCV
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More